Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Signadori Bio

Request full access

The next-generation cellular immunotherapy for cancer cure

Paris, FranceFounded 2025Biotech & Life Sciences

About Signadori Bio

Signadori Bio is a preclinical-stage biopharmaceutical company that emerged in 2025 as a strategic collaboration between the European life sciences venture capital firm Sofinnova Partners and Gustave Roussy, a premier cancer center in Europe. The company was established with scientific founders Dr. Jean-Luc Perfettini and Professor Nathalie Chaput, leveraging their research conducted at Gustave Roussy. The venture is steered by CEO Matthieu Coutet, who is also a Partner at Sofinnova Partners.

The firm is focused on developing a next-generation cell therapy platform to address the complexities of treating solid tumors. Signadori Bio's core technology centers on a monocyte-based cell therapy approach. This involves harnessing the immune potential of gene-modified monocytes and macrophages to overcome the challenging tumor microenvironment. The company's business model is centered on advancing its proprietary platform from the preclinical stage through to clinical trials and eventual commercialization. As a venture capital-backed entity, its operations are financed through strategic investments. In March 2025, it was announced as one of the first companies to receive investment from Sofinnova's €165 million Biovelocita II fund, which is supported by major pharmaceutical players like Amgen and Bristol Myers Squibb. Invivo Partners also joined as an investor, further strengthening the company's financial and strategic foundation.

Headquartered in Paris, France, Signadori Bio is currently in the preclinical stage of development. A significant milestone was the establishment of a partnership with eXmoor Pharma in June 2025 to accelerate the development and manufacturing of its lead candidate. This collaboration is designed to guide the therapy program through critical development milestones, with a long-term goal of GMP-compliant manufacturing for first-in-human clinical trials. The company aims to make more information public as it moves out of stealth mode.

Source: Dealroom company data

At a glance

Status
Operational
Employees
7
Open positions
None listed
Dealroom signal
45.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Oncology, Immunotherapy, observatoire industrial tech, DT and LS, observatoire healthtech, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC May 2026 $12M $49M Sofinnova Partners · Invivo Partners · Taiho Ventures ↗
EARLY VC✓Equity / VC Apr 2025 $0 — Invivo Partners ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Signadori Bio in the Paris ecosystem

Live from Dealroom

The Signadori Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

Series A1 investor entered at this stage

  • Invivo Partners
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇫🇷 France50%
🇺🇸 United States25%
🇪🇸 Spain12.5%
🇬🇧 United Kingdom12.5%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Signadori Bio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Signadori Bio’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.